Skip to main content
OpenTrials
Completed

NCT Number: NCT04010266

RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use

This is a single-center, prospective, randomized, controlled study of the appliedVR RelieVRx headset in subjects undergoing Total Knee Arthroplasty (TKA). This study will evaluate two primary endpoints - effectiveness of a single use of RelieVRx in the reduction of acute postoperative pain by 20%; and overall effectiveness of RelieVRx as an opioid-sparing intervention, where opioid consumption is reduced by at least 20% over a 90-day postoperative period in the interventional, standard of care (SOC) plus RelieVRx group compared to the control, SOC group.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Geisinger Medical Center, Danville, Pennsylvania, United States

Loading trial locations.

About this study

This is a single-center, prospective, randomized, controlled study of the appliedVR RelieVRx headset in subjects undergoing Total Knee Arthroplasty (TKA). Patients will be randomized to one of the two groups after study enrollment, and patients in the test arm will be educated about the device preoperatively to facilitate its use in the acute post-operative period. The goals of VR will be presented in the context of an alternate method of pain control to opioids. This study will evaluate two primary endpoints - effectiveness of a single use of RelieVRx in the reduction of acute postoperative pain by 20%; and overall effectiveness of RelieVRx as an opioid-sparing intervention, where opioid consumption is reduced by at least 20% over a 90-day postoperative period in the interventional, standard of care (SOC) plus RelieVRx group compared to the control, SOC group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is ≥ 18 years old
  • Subject is willing and able to read, comprehend, and sign the study informed consent form in English prior to study specific procedure
  • Subject is scheduled for Total Knee Arthroplasty (TKA) surgery
  • Subject has a score of 1-3 based on the American Society of Anesthesiologists Physical Status Classification System
  • Subject attended the pre-op Total Joint Arthroplasty Patient Education class (Proven Recovery Program©)
  • Subject agrees to be enrolled in Force Therapeutics, a web-based, digital rehabilitation and education program
  • Subject has family member or community support during post-surgical recovery period

Exclusion criteria

  • Diagnosed with chronic pain syndrome
  • Body Mass Index (BMI) ≥ 40
  • Current tobacco user at time of surgery
  • Uncontrolled sleep apnea
  • Bilateral TKA
  • Current or recent history (in past year) of substance abuse disorder
  • Uncontrolled diabetes (HbA1c ≥ 7.0) 7.8 at time of surgery
  • History of Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT)
  • Currently being treated with blood thinners at time of surgery
  • Diagnosis of Rheumatoid Arthritis (RA)
  • Has Methicillin-resistant Staphylococcus aureus (MRSA)
  • Currently pregnant/breastfeeding or planning to in the next 3 months
  • Comorbidities including neurological, psychosocial, sensory, or other disorders that may impact pain perception
  • Diagnosis of epilepsy, dementia, migraines, or other neurological disorders that may prevent VR usage, and/or other medical conditions predisposed to nausea and dizziness
  • Hypersensitivity to flashing lights or motion
  • Claustrophobia
  • Lack of stereoscopic vision
  • Severe hearing impairment
  • Injury to eyes, face, or neck that prevents comfortable VR usage

Treatment and study plan

RelieVRx headset

Device

RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain

multi-modality pain management

Drug

combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids

Primary outcomes

  1. Acute Postoperative Pain

    Time frame: 90 days

    Visual Analog Pain scale; worst 0-10 best

  2. Opioid Consumption

    Time frame: 90 days

    Morphine Milligram Equivalents (MME)

Secondary outcomes

  1. KOOS Jr. Score

    Time frame: 90 days

    short form of knee injury and osteoarthritis outcome score; worst 0 - 100 best

  2. Veterans RAND 12 Health Survey (VR-12) - Physical Component Score

    Time frame: 90 days

    This is a measure of quality of life. The VR-12 provides a physical component score (i.e., physical health domain) that provides larger weights for four of the domains (physical function, role-physical, bodily pain, and general health). This is a 12 items survey. VR-12 scores are standardized using a T-score metric with a mean of 50 and a standard deviation of 10. Larger values imply greater physical function and quality of life.

Sponsors and collaborators

Lead sponsor

AppliedVR Inc.

Industry

Collaborators

  • Geisinger Clinic
  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Safety and Effectiveness of Virtual Reality Utilizing RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
Jul 8, 2019
Registry last updated
Feb 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.